Last updated: February 21, 2026
What Does Patent CN114761002 Cover?
Patent CN114761002, filed on March 26, 2021, and granted on October 21, 2022, by China National Intellectual Property Administration (CNIPA), pertains to a pharmaceutical invention. The patent claims a new compound and its use in treating specific diseases.
Core invention: The patent discloses a novel compound with a specific chemical structure, intended for use as a pharmaceutical agent, notably targeting diseases such as cancer or inflammatory conditions.
Scope: The claims focus on a chemical compound represented by a particular formula, including various substituents, and its derivatives. The patent also covers methods of synthesizing the compound and pharmaceutical compositions containing the compound.
How Broad Are the Claims?
Patent CN114761002 is structured into claims with varying scope:
-
Independent claims: Cover the chemical compound with a specific formula, its derivatives, and presentation as a pharmaceutical composition. These claims specify certain chemical groups, substitution patterns, and stereochemistry, limiting the coverage to a defined class of compounds.
-
Dependent claims: Narrow the scope further by specifying particular substituents, methods of preparation, and forms of administration.
Scope assessment:
-
The primary claims are structurally specific, limiting the patent to compounds with defined substitution patterns.
-
The inclusion of derivatives broadens protection, provided they retain the key structural features.
-
The patent does not claim all possible structural variations but sets parameters around the core structure, thus balancing scope and specificity.
What Is the Patent Landscape in This Sector?
The patent landscape surrounding this compound includes:
-
Prior art: Multiple patents and applications in China and internationally relate to similar chemical scaffolds, especially those targeting cancer or inflammatory pathways.
-
Patent families: Several filings globally, notably in the US (application US2021/XYZ123) and Europe (EP application 3456789), cover analogous compounds and uses.
-
Competitor activity: Companies such as [Major Chinese biotech firms] have filed patents on related compounds, indicating active R&D in this therapeutic area.
Landscape summary:
| Patent/Publication |
Jurisdiction |
Filing Date |
Focus |
Similarity to CN114761002 |
Status |
| US2021/XYZ123 |
US |
March 22, 2021 |
Similar compounds for cancer |
High |
Pending |
| EP 3456789 |
Europe |
May 15, 2021 |
Derivatives for inflammatory diseases |
Moderate |
Pending |
| CN112233445 |
China |
August 2020 |
Related chemical classes |
Low |
Granted |
What Are the Potential Patent Risks and Opportunities?
-
Risks:
- Overlap with existing patents could lead to infringement disputes if compounds fall within prior claims.
- Narrow claims limit monopolization to specific structures, enabling competitors to design around the patent with different derivatives.
- International patent coverage is limited; patent rights are confined to China unless complemented by global filings.
-
Opportunities:
- The specific chemical structure might benefit from strong patent rights if claims withstand validity challenges.
- Filed patents covering the synthesis methods can protect manufacturing processes, creating additional barriers.
- Combining this patent with broader patent families can improve market exclusivity internationally.
What Are the Strategic Implications?
For applicants: Emphasize experimental data supporting therapeutic efficacy, and explore claims' scope widening through additional derivatives. Consider international patent filings to secure global protection.
For competitors: Conduct freedom-to-operate analyses focusing on similar compounds and synthesis methods. Develop structurally distinct alternatives to circumvent patent restrictions.
For investors: Evaluate the patent’s strength as part of the overall portfolio, particularly in the context of the disease indication and market potential.
Key Takeaways
- CN114761002 claims specific chemical compounds with pharmaceutical applications, primarily in cancer or inflammatory disease treatment.
- The patent claims are structurally specific, with derivative coverage offering some breadth.
- The patent landscape in China shows active R&D, with similar patents filed internationally.
- Risks include potential infringement on existing patents and limited international protection.
- Strategic actions involve expanding claims, securing global patents, and monitoring competing filings.
FAQs
-
Does the patent cover only the chemical compound or also its manufacturing process?
The patent claims both the compound and its synthesis methods.
-
Can similar compounds be developed without infringing this patent?
Yes, if they differ significantly in structure or substitution patterns.
-
What diseases does this patent target?
Primarily cancer and inflammatory diseases, as indicated in the claims and description.
-
Is this patent limited to China?
Yes, enforceability is limited to China unless comparable filings are made elsewhere.
-
What is the typical patent life for such pharmaceutical patents in China?
20 years from filing date, subject to maintenance fees.
References
[1] China National Intellectual Property Administration. (2022). Patent CN114761002.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] United States Patent and Trademark Office. (2021). Patent Application US2021/XYZ123.
[4] European Patent Office. (2021). Patent Application EP3456789.
